Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 3
1996 1
1997 1
1998 4
1999 3
2000 3
2002 1
2003 1
2004 1
2005 3
2006 1
2007 3
2008 3
2009 3
2010 1
2011 3
2012 2
2013 2
2014 2
2015 4
2016 11
2017 8
2018 11
2019 5
2020 1
2022 2
2024 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Similar articles for PMID: 32132045

77 results

Results by year

Filters applied: . Clear all
Page 1
A randomized, open-label, multicenter, phase II study evaluating the efficacy and safety of BTH1677 (1,3-1,6 beta glucan; Imprime PGG) in combination with cetuximab and chemotherapy in patients with advanced non-small cell lung cancer.
Thomas M, Sadjadian P, Kollmeier J, Lowe J, Mattson P, Trout JR, Gargano M, Patchen ML, Walsh R, Beliveau M, Marier JF, Bose N, Gorden K, Schneller F 3rd. Thomas M, et al. Invest New Drugs. 2017 Jun;35(3):345-358. doi: 10.1007/s10637-017-0450-3. Epub 2017 Mar 16. Invest New Drugs. 2017. PMID: 28303530 Free PMC article. Clinical Trial.
A randomized, controlled trial evaluating the efficacy and safety of BTH1677 in combination with bevacizumab, carboplatin, and paclitaxel in first-line treatment of advanced non-small cell lung cancer.
Engel-Riedel W, Lowe J, Mattson P, Richard Trout J, Huhn RD, Gargano M, Patchen ML, Walsh R, Trinh MM, Dupuis M, Schneller F. Engel-Riedel W, et al. J Immunother Cancer. 2018 Feb 27;6(1):16. doi: 10.1186/s40425-018-0324-z. J Immunother Cancer. 2018. PMID: 29486797 Free PMC article. Clinical Trial.
Imprime PGG-Mediated Anti-Cancer Immune Activation Requires Immune Complex Formation.
Chan AS, Jonas AB, Qiu X, Ottoson NR, Walsh RM, Gorden KB, Harrison B, Maimonis PJ, Leonardo SM, Ertelt KE, Danielson ME, Michel KS, Nelson M, Graff JR, Patchen ML, Bose N. Chan AS, et al. PLoS One. 2016 Nov 3;11(11):e0165909. doi: 10.1371/journal.pone.0165909. eCollection 2016. PLoS One. 2016. PMID: 27812183 Free PMC article.
Immune Pharmacodynamic Responses of the Novel Cancer Immunotherapeutic Imprime PGG in Healthy Volunteers.
Bose N, Ottoson NR, Qiu X, Harrison B, Lowe JR, Uhlik MT, Rathmann BT, Kangas TO, Jordan LR, Ertelt KE, Jonas AB, Walsh RM, Chan ASH, Fulton RB, Leonardo SM, Fraser KA, Gorden KB, Matson MA, Graff JR, Huhn RD. Bose N, et al. J Immunol. 2019 May 15;202(10):2945-2956. doi: 10.4049/jimmunol.1801533. Epub 2019 Apr 15. J Immunol. 2019. PMID: 30988115 Clinical Trial.
77 results